July 2, 2024 – TenNor will present a series of posters on its investigational new drug rifaquizinone (TNP-2092) for the treatment of medical device infections at IDWeek 2024 to be held in Los Angeles, USA from October 16 to 20, 2024.

TenNor and its collaborators from the Rothman Orthopedic Institute, Huashan Hospital of Fudan University, Velocity Clinical Research, Allucent, Pharmaron, WuXi AppTec, University of North Texas Health Science Center and Zhongnan Hospital of Wuhan University submitted eight poster presentations on rifaquizinone to IDWeek 2024. All abstracts have been accepted.

3. Safety Study of Rifaquizinone in Dogs Following Intra-Articular Administration （ID: 1829121）

8. Rifaquizinone for the Treatment of Acute Bacterial Skin and Skin Structure Infections: A Multicenter, Double-Blind, Randomized, Active-Controlled, Phase 2 Trial （ID: 1820809）

IDWeek is an important conference jointly organized by the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), the Pediatric Infectious Diseases Society (PIDS), and the Society of Infectious Disease Pharmacists (SIDP).

Rifaquizinone is a multi-targeting drug conjugate specifically designed and developed for the treatment of medical device infections. It exerts its antibacterial activity by inhibiting bacterial RNA polymerase, DNA gyrase and topoisomerase IV. It shows potent activity against bacteria commonly resistant to current antibiotics, such as methicillin-resistant and quinolone-resistant Staphylococcus aureus (MRSA and QRSA), and bacterial biofilm infections associated with implanted medical devices. Rifaquizinone exhibits lower frequencies for the development of resistance than the most of traditional antibiotics.

TenNor has completed six phase 1 and phase 2 clinical trials for rifaquizinone for injection in China and the United States and is planning to conduct multiregional phase 3 clinical trials for the treatment of prosthetic joint infections (PJI) and acute bacterial skin and skin structure infections (ABSSSI). Rifaquizinone for injection has received Qualified Infectious Disease Product (QIDP), Fast Track and Orphan Drug designations form the FDA.

Annex:

About TenNor Therapeutics

Incorporated in 2013, TenNor Therapeutics is a near-commercial stage biotechnology company dedicated to the discovery, development and commercialization of differentiated therapies to address unmet medical needs in disease areas associated with bacterial infections and bacterial metabolism. Empowered by its proprietary multi-targeting conjugate molecule technology, TenNor Therapeutics aims to deliver the best therapeutic solutions to overcome the limitations of conventional treatments and improve patient outcomes. As of July 24, 2025, TenNor Therapeutics had built a differentiated pipeline of seven innovative assets, including three Core Products, namely, rifasutenizol (TNP-2198), the world’s first and only new molecular entity (“NME”) drug candidate developed for the treatment of Helicobacter pylori (“H. pylori”) infection; rifaquizinone (TNP-2092) injection, a potential first-in-class, triple-targeting antibacterial drug candidate for the treatment of implant-associated bacterial infections; and TNP-2092 oral, the world’s first multi-targeting antibacterial drug candidate for the treatment of diseases associated with gut bacterial metabolism.

For more information, please visit: www.tennortherapeutics.com